Published in J Clin Pathol on November 01, 1995
Role of local cytokines in increased gastric expression of the secretory component in Helicobacter pylori infection. Infect Immun (1999) 0.89
Human gastric B cell responses can be induced by intestinal immunisation. Gut (2001) 0.86
Local and systemic immune and inflammatory responses to Helicobacter pylori strains. Clin Diagn Lab Immunol (2005) 0.85
Unidentified curved bacilli on gastric epithelium in active chronic gastritis. Lancet (1983) 23.90
Helicobacter pylori infection and the risk of gastric carcinoma. N Engl J Med (1991) 23.89
Association between infection with Helicobacter pylori and risk of gastric cancer: evidence from a prospective investigation. BMJ (1991) 9.88
Helicobacter pylori and the pathogenesis of gastroduodenal inflammation. J Infect Dis (1990) 6.90
Effect of treatment of Helicobacter pylori infection on the long-term recurrence of gastric or duodenal ulcer. A randomized, controlled study. Ann Intern Med (1992) 6.64
Campylobacter pylori antibodies in humans. Ann Intern Med (1988) 6.02
Prevalence of Helicobacter pylori infection and histologic gastritis in asymptomatic persons. N Engl J Med (1989) 5.78
Campylobacter pylori detected noninvasively by the 13C-urea breath test. Lancet (1987) 5.02
Diagnostic value of decreasing IgG, IgA, and IgM antibody titres after eradication of Helicobacter pylori. Lancet (1992) 4.54
Systemic and local antibody responses to gastric Campylobacter pyloridis in non-ulcer dyspepsia. Gut (1986) 4.47
A sensitive and specific serologic test for detection of Campylobacter pylori infection. Gastroenterology (1989) 3.66
Gastric lymphoid follicles in Helicobacter pylori infection: frequency, distribution, and response to triple therapy. Hum Pathol (1993) 2.96
Carbon-14 urea breath test for the diagnosis of Campylobacter pylori associated gastritis. J Nucl Med (1988) 2.80
Duodenal ulcer: the villain unmasked? BMJ (1991) 2.30
Lymphoid follicles in antral mucosa: immune response to Campylobacter pylori? J Clin Pathol (1989) 2.02
Immune response of the gastric mucosa to Campylobacter pylori. Scand J Gastroenterol Suppl (1988) 1.93
Long term serological surveillance after treatment of Helicobacter pylori infection. Gut (1991) 1.90
Seroconversion for Helicobacter pylori. Lancet (1993) 1.88
Value of serology (ELISA and immunoblotting) for the diagnosis of Campylobacter pylori infection. Digestion (1989) 1.73
Effect of transport medium and transportation time on culture of Helicobacter pylori from gastric biopsy specimens. J Clin Pathol (1993) 1.66
Treatment of peptic ulcers caused by Helicobacter pylori. N Engl J Med (1993) 1.52
Observer homogeneity in the histologic diagnosis of Helicobacter pylori. Latent class analysis, kappa coefficient, and repeat frequency. Scand J Gastroenterol (1992) 1.10
Eighteen month follow up of Helicobacter pylori positive children treated with amoxycillin and tinidazole. Gut (1992) 1.07
Helicobacter pylori infection in peptic ulcer disease. Scand J Gastroenterol (1993) 0.95
Antibodies to Helicobacter pylori and pepsinogen levels in children from Costa Rica: comparison of two areas with different risks for stomach cancer. Cancer Epidemiol Biomarkers Prev (1993) 0.94
Decontamination of the digestive tract and oropharynx in ICU patients. N Engl J Med (2009) 8.30
Chronic experimental colitis induced by dextran sulphate sodium (DSS) is characterized by Th1 and Th2 cytokines. Clin Exp Immunol (1998) 5.77
Long-term sequelae of Helicobacter pylori gastritis. Lancet (1995) 4.26
Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication. N Engl J Med (1996) 4.11
Long-term treatment with omeprazole for refractory reflux esophagitis: efficacy and safety. Ann Intern Med (1994) 4.00
Effect of omeprazole and ranitidine on ulcer healing and relapse rates in patients with benign gastric ulcer. N Engl J Med (1989) 3.03
Inactive urokinase and increased levels of its inhibitor type 1 in colorectal cancer liver metastasis. Gastroenterology (1994) 2.22
Increase of Helicobacter pylori-associated corpus gastritis during acid suppressive therapy: implications for long-term safety. Am J Gastroenterol (1995) 2.12
Acinetobacter species identification by using tRNA spacer fingerprinting. J Clin Microbiol (1996) 1.99
Long term serological surveillance after treatment of Helicobacter pylori infection. Gut (1991) 1.90
Definition of polymorphisms and haplotypes in the interleukin-12B gene: association with IL-12 production but not with Crohn's disease. Genes Immun (2004) 1.89
Seroconversion for Helicobacter pylori. Lancet (1993) 1.88
Secretion of tumour necrosis factor alpha and lymphotoxin alpha in relation to polymorphisms in the TNF genes and HLA-DR alleles. Relevance for inflammatory bowel disease. Scand J Immunol (1996) 1.86
Double-blind multicentre comparison of omeprazole and ranitidine in the treatment of reflux oesophagitis. Lancet (1987) 1.83
HLA-DW3 associated with coeliac disease. Lancet (1976) 1.79
Cholesterol crystal embolization in the Netherlands. Arch Intern Med (1996) 1.74
Treatment of the dumping syndrome with the somatostatin analogue SMS 201-995. Ann Surg (1988) 1.72
Tissue levels of matrix metalloproteinases MMP-2 and MMP-9 are related to the overall survival of patients with gastric carcinoma. Br J Cancer (1996) 1.71
Effect of transport medium and transportation time on culture of Helicobacter pylori from gastric biopsy specimens. J Clin Pathol (1993) 1.66
HLA-DR phenotypes in Spanish coeliac children: their contribution to the understanding of the genetics of the disease. Gut (1983) 1.65
IL1B gene polymorphisms influence the course and severity of inflammatory bowel disease. Immunogenetics (1999) 1.62
Hypergastrinaemia during long-term omeprazole therapy: influences of vagal nerve function, gastric emptying and Helicobacter pylori infection. Aliment Pharmacol Ther (1998) 1.61
Radioimmunoassay of cholecystokinin in human tissue and plasma. Clin Chim Acta (1983) 1.61
Genetic basis of gluten-sentitive enteropathy. Gastroenterology (1978) 1.60
Cholecystokinin receptors in human pancreas and gallbladder muscle: a comparative study. Gastroenterology (1996) 1.55
Satiety effects of cholecystokinin in humans. Gastroenterology (1994) 1.55
Interleukin-1 receptor antagonist gene polymorphism and multiple sclerosis. Lancet (1995) 1.53
An overview of the current diagnosis and recent developments in neuroendocrine tumours of the gastroenteropancreatic tract: the diagnostic approach. Neth J Med (2011) 1.53
Accuracy and cost-effectiveness of a new strategy to screen for celiac disease in children with Down syndrome. J Pediatr (2000) 1.53
Nonulcer dyspepsia in a Dutch working population and Helicobacter pylori. Ulcer history as an explanation of an apparent association. Arch Intern Med (1995) 1.52
Evidence of genetic heterogeneity in IBD: 1. The interleukin-1 receptor antagonist in the predisposition to suffer from ulcerative colitis. Eur J Gastroenterol Hepatol (1996) 1.52
Effect of oral zinc supplementation on metallothionein and superoxide dismutase concentrations in patients with inflammatory bowel disease. J Gastroenterol Hepatol (1995) 1.52
Disaccharidase activity and jejunal morphology in coeliac disease. Q J Med (1972) 1.48
Current methods to diagnose the unresponsive and complicated forms of coeliac disease. Eur J Intern Med (2010) 1.47
Serum gastrin and mucosal somatostatin in Helicobacter pylori-associated gastritis. Scand J Gastroenterol (1995) 1.47
Upper gastrointestinal complaints and complications in chronic rheumatic patients in comparison with other chronic diseases. Br J Rheumatol (1992) 1.46
Clinical presentation of Helicobacter pylori-positive and -negative functional dyspepsia. J Gastroenterol Hepatol (2000) 1.46
Clinical aspects of Crohn's disease of the upper gastrointestinal tract: a comparison with distal Crohn's disease. Am J Gastroenterol (1997) 1.46
Association of NOD2/CARD15 mutations with previous surgical procedures in Crohn's disease. Rev Esp Enferm Dig (2005) 1.44
Endemic and epidemic acinetobacter species in a university hospital: an 8-year survey. J Clin Microbiol (2009) 1.43
TNF-alpha promoter polymorphisms, production and susceptibility to multiple sclerosis in different groups of patients. J Neuroimmunol (1997) 1.43
Gall bladder emptying in severe idiopathic constipation. Gut (1999) 1.43
Seroreactivity of patients with Crohn's disease with lymph nodes of primed nude mice is independent of the tissue used for priming. Gastroenterology (1989) 1.40
Allelic polymorphism in IL-1 beta and IL-1 receptor antagonist (IL-1Ra) genes in inflammatory bowel disease. Clin Exp Immunol (1995) 1.39
[Optimizing treatment of complicated forms of inflammatory bowel disease. Fistulizing Crohn's disease]. An Med Interna (2003) 1.39
[Linezolid, an agent from a new class of antibiotics]. Ned Tijdschr Geneeskd (2004) 1.39
Gallbladder motility after duodenum-preserving resection of the head of the pancreas. Scand J Gastroenterol (1997) 1.38
Omeprazole in peptic ulcers resistant to histamine H2-receptor antagonists. Aliment Pharmacol Ther (1987) 1.38
Familial incidence of Crohn's disease in The Netherlands and a review of the literature. Gastroenterology (1984) 1.36
Presence of Helicobacter pylori in the oral cavity, oesophagus, stomach and faeces of patients with gastritis. Eur J Clin Microbiol Infect Dis (1995) 1.35
A TaqI polymorphism in the 3'UTR of the IL-12 p40 gene correlates with increased IL-12 secretion. Genes Immun (2002) 1.33
Epidemiology and survival in patients with carcinoid disease in The Netherlands. An epidemiological study with 2391 patients. Ann Oncol (2001) 1.33
Distribution of four polymorphisms in the tumour necrosis factor (TNF) genes in patients with inflammatory bowel disease (IBD). Clin Exp Immunol (1996) 1.33
Importance of the fiberoptic endoscope cleaning procedure for detection of Helicobacter pylori in gastric biopsy specimens by PCR. J Clin Microbiol (1994) 1.32
Pneumatosis cystoides intestinalis in intestinal pseudoobstruction. Resolution after therapy with metronidazole. Dig Dis Sci (1992) 1.29
Cholecystokinin-octapeptidelike immunoreactivity in human plasma. Gastroenterology (1982) 1.29
ELISA assay for quantitative measurement of human immunoglobulins IgA, IgG, and IgM in nanograms. J Immunol Methods (1983) 1.28
Proximal Crohn's disease: review of the clinicopathologic features and therapy. Inflamm Bowel Dis (2001) 1.26
The value of screening and central registration of families with familial adenomatous polyposis. A study of 82 families in The Netherlands. Dis Colon Rectum (1990) 1.25
Epidemiology of proctocolitis in the region of Leiden, The Netherlands. A population study from 1979 to 1983. Scand J Gastroenterol (1987) 1.23
Effect of long-term treatment with omeprazole on serum gastrin and serum group A and C pepsinogens in patients with reflux esophagitis. Gastroenterology (1990) 1.19
The effect of loxiglumide (CR-1505) on basal and bombesin-stimulated gallbladder volume in man. Eur J Pharmacol (1989) 1.19
Prognostic relevance of plasminogen activators and their inhibitors in colorectal cancer. Cancer Res (1994) 1.18
Urokinase receptor and colorectal cancer survival. Lancet (1994) 1.18
Endoscopic regression of Barrett's oesophagus during omeprazole treatment; a randomised double blind study. Gut (1999) 1.18
Epidemiology of Crohn's disease in Regio Leiden, The Netherlands. A population study from 1979 to 1983. Gastroenterology (1987) 1.17
Are activity indices helpful in assessing active intestinal inflammation in Crohn's disease? Gut (1989) 1.17
Cytokine gene polymorphisms and the risk of adenocarcinoma of the stomach in the European prospective investigation into cancer and nutrition (EPIC-EURGAST). Ann Oncol (2008) 1.16
Influence of age and Helicobacter pylori infection on serum pepsinogens in healthy blood transfusion donors. Gut (1992) 1.16
The long-term prognosis of ileorectal anastomosis and proctocolectomy in Crohn's disease. Scand J Gastroenterol (1976) 1.16
Postprandial gallbladder motility during long term treatment with the long-acting somatostatin analog SMS 201-995 in acromegaly. J Clin Endocrinol Metab (1989) 1.15
Crohn's disease of the upper gastrointestinal tract. Neth J Med (1997) 1.14
Superoxide dismutases in gastric and esophageal cancer and the prognostic impact in gastric cancer. Clin Cancer Res (2000) 1.14
Serum concentrations of immunoreactive calcitonin in patients with hypergastrinaemia. Digestion (1980) 1.13
Effect of graded physiologic doses of cholecystokinin on gallbladder contraction measured by ultrasonography. Determination of threshold, dose-response relationships and comparison with intraduodenal bilirubin output. Gastroenterology (1985) 1.13
Prospective comparative study of the influence of postoperative bile reflux on gastric mucosal histology and Campylobacter pylori infection. Gut (1989) 1.11
Pancreatic enzyme response to a liquid meal and to hormonal stimulation. Correlation with plasma secretin and cholecystokinin levels. J Clin Invest (1985) 1.11
The dumping syndrome. Current insights into pathophysiology, diagnosis and treatment. Scand J Gastroenterol Suppl (1997) 1.11
Non-lymphoid and lymphoid cells in acute, chronic and relapsing experimental colitis. Clin Exp Immunol (1995) 1.11
A computerized method for rapid quantification of gallbladder volume from real-time sonograms. Radiology (1985) 1.10
Superoxide dismutases in relation to the overall survival of colorectal cancer patients. Br J Cancer (1998) 1.10
Anti-CD11b/CD18 antibodies reduce inflammation in acute colitis in rats. Clin Exp Immunol (1995) 1.09
Plasminogen activators and tumor development in the human colon: activity levels in normal mucosa, adenomatous polyps, and adenocarcinomas. Cancer Res (1987) 1.09
Motor and sensory function of the proximal stomach in reflux disease and after laparoscopic Nissen fundoplication. Am J Gastroenterol (1999) 1.09
Effect of oral omeprazole on serum gastrin and serum pepsinogen I levels. Gastroenterology (1984) 1.08
Imbalance of plasminogen activators and their inhibitors in human colorectal neoplasia. Implications of urokinase in colorectal carcinogenesis. Gastroenterology (1991) 1.08
[Nitric oxide and inflammatory bowel disease]. Rev Esp Enferm Dig (1998) 1.08
Clinical significance of pepsinogen A isozymogens, serum pepsinogen A and C levels, and serum gastrin levels. Cancer (1987) 1.08
Epidemiology of multiple Acinetobacter outbreaks in The Netherlands during the period 1999-2001. Clin Microbiol Infect (2006) 1.08
Amputation-sparing treatment by nature: "surgical" maggots revisited. Clin Infect Dis (2002) 1.07
Prevalence of Acinetobacter baumannii and other Acinetobacter spp. in faecal samples from non-hospitalised individuals. Clin Microbiol Infect (2005) 1.06
Plasminogen activator profiles in neoplastic tissues of the human colon. Cancer Res (1988) 1.06